Table A7.

The proportion of patients with adjustment among DOAC users concomitant with interacting drugs

Concomitant with	Cases	Control	P‐value
PK (n = 942; missing 235)	n = 140	n = 567
With adjustment * ; n (%)	23 (16.4)	67 (11.8)	.14
Dose increase	3 (2.1)	12 (2.1)	.98
Dose decrease	11 (6.4)	9 (1.9)	.004
Switch to other DOAC	11 (7.9)	44 (7.8)	.97
PD (n = 276; missing 73)	n = 67	n = 147
With adjustment; n (%)	10 (14.9)	15 (10.2)	.32
Dose increase	2 (3.0)	4 (2.7)	.91
Dose decrease	2 (3.0)	3 (2.0)	.67
Switch to other DOAC	6 (9.0)	8 (5.4)	.34

PK, P‐gP inhibitors or CYP3A4 inhibitors; PD, drugs with pharmacodynamic interaction.

^* Adjustment include dose adjustment and switch to other DOACs.